Skip to search formSkip to main contentSkip to account menu

abarelix

Known as: N-acetyl-3-(2-naphthalenyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridinyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N(6)-(1-methylethyl)-L-lysyl-L-prolyl-D-alaninamide, abarelix [Chemical/Ingredient] 
A synthetic decapeptide and antagonist of naturally occurring gonadotropin-releasing hormone (GnRH). Abarelix directly and competitively binds to and… 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (2)

Hormone AntagonistsOligopeptides

Narrower (2)

PPI-149Plenaxis

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
Pharmacotherapeutic Targeting of G Protein-Coupled Receptors in Oncology: Examples of Approved Therapies and Emerging Concepts
G protein-coupled receptors (GPCRs) are involved in numerous physio-pathological processes, including the stimulation of cancer… 
Review
2012
Review
2012
Gonadotropin‐releasing hormone: An update review of the antagonists versus agonists
Gonadotropin‐releasing hormone agonists and antagonists provide androgen‐deprivation therapy for prostate cancer. Unlike agonists… 
2012
2012
Prostate cancer: Making the switch from LHRH antagonist to LHRH agonist
One very important issue faced by clinicians managing patients with prostate cancer is whether after initiating a man on a pure… 
Review
2011
Review
2011
Biochemistry, molecular biology and cell biology of gonadotropin-releasing hormone antagonists
Purpose of review Gonadotropin-releasing hormone (GnRH) receptors are not only detected in the central nervous system but also in… 
Review
2009
Review
2009
Abarelix and other gonadotrophin‐releasing hormone antagonists in prostate cancer
Hormonal therapy is the main recommended treatment for locally advanced and metastatic prostate cancer. Luteinizing hormone… 
Review
2006
Review
2006
Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer.
Abarelix, a gonadotropin-releasing hormone antagonist, with its indication for advanced symptomatic prostate cancer, represents… 
Review
2004
Review
2004
Hormone therapy in prostate cancer: LHRH antagonists versus LHRH analogues.
Review
2003
Review
2003
Luteinizing hormone-releasing hormone agonists in the treatment of men with prostate cancer: timing, alternatives, and the 1-year implant.
Highly Cited
2002
Highly Cited
2002
Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix.
We describe the pharmacological profile in rats and monkeys of degarelix (FE200486), a member of a new class of long-acting… 
Highly Cited
2001
Highly Cited
2001
GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6.
A series of antagonists of gonadotropin-releasing hormone (GnRH) of the general formula Ac-D2Nal-D4Cpa-D3Pal-Ser-4Aph/4Amf(P… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)